Risk of Hypercholesterolemia for Cardiovascular Disease and the Population Attributable Fraction in a 24-year Japanese Cohort Study-Reference-Cited by-同舟云学术

Risk of Hypercholesterolemia for Cardiovascular Disease and the Population Attributable Fraction in a 24-year Japanese Cohort Study

Published:2015 Issue:1 Volume:22 Page:95-107
ISSN:1340-3478
Container-title:Journal of Atherosclerosis and Thrombosis
language:en
Short-container-title:JAT

Author:

Sugiyama Daisuke¹,Okamura Tomonori¹,Watanabe Makoto²,Higashiyama Aya³,Okuda Nagako⁴,Nakamura Yasuyuki⁵,Hozawa Atsushi⁶,Kita Yoshikuni⁷,Kadota Aya⁸,Murakami Yoshitaka⁹,Miyamatsu Naomi¹⁰,Ohkubo Takayoshi¹¹,Hayakawa Takehito¹²,Miyamoto Yoshihiro²,Miura Katsuyuki⁸,Okayama Akira¹³,Ueshima Hirotsugu⁸,

Affiliation:

1. Department of Preventive Medicine and Public Health, Keio University School of Medicine

2. Department of Preventive Cardiology, National Cerebral and Cardiovascular Center

3. Department of Preventive Medicine and Epidemiologic Informatics, National Cerebral and Cardiovascular Center

4. Department of Health and Nutrition University of Human Arts and Sciences

5. Department of Cardiovascular Epidemiology, Kyoto Women’s University

6. Preventive Medicine and Epidemiology, Tohoku Medical Megabank Organization, Tohoku University

7. Department of Nursing, Tsuruga Nursing University

8. Center for Epidemiologic Research in Asia/Department of Public Health, Shiga University of Medical Science

9. Department of Medical Statistics, Toho University School of Medicine

10. Department of Clinical Nursing, Shiga University of Medical Science

11. Department of Hygiene and Public Health, Teikyo University School of Medicine

12. Department of Hygiene and Preventive Medicine, Fukushima Medical University

13. Research institute for lifestyle-related disease prevention

Publisher

Japan Atherosclerosis Society

Subject

Biochemistry, medical,Cardiology and Cardiovascular Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/jat/22/1/22_25908/_pdf

Reference38 articles.

1. 1) http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/suikei11/ (in Japanese)

2. 2) Emberson JR, Whincup PH, Morris RW, Walker M: Reassessing the contribution of serum total cholesterol, blood pressure and cigarette smoking to the aetiology of coronary heart disease: impact of regression dilution bias. Eur Heart J, 2003; 24: 1719-1726

3. 3) Singh-Manoux A, Nabi H, Shipley M, Guéguen A, Sabia S, Dugravot A, Marmot M, Kivimaki M: The role of conventional risk factors in explaining social inequalities in coronary heart disease: the relative and absolute approaches to risk. Epidemiology, 2008; 19: 599-605

4. 4) Grau M, Subirana I, Elosua R, Fitó M, Covas MI, Sala J, Masiá R, Ramos R, Solanas P, Cordon F, Nieto FJ, Marrugat J; REGICOR Investigators: Why should population attributable fractions be periodically recalculated? An example from cardiovascular risk estimation in southern Europe. Prev Med, 2010; 51: 78-84

5. 5) Woodward M, Martiniuk A, Lee CM, Lam TH, Vanderhoorn S, Ueshima H, Fang X, Kim HC, Rodgers A, Patel A, Jamrozik K, Huxley R; Asia Pacific Cohort Studies Collaboration: Elevated total cholesterol: its prevalence and population attributable fraction for mortality from coronary heart disease and ischaemic stroke in the Asia-Pacific region. Eur J Cardiovasc Prev Rehabil, 2008; 15: 397-401

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022;Journal of Atherosclerosis and Thrombosis;2023

2. Therapeutic potential of paeoniflorin in atherosclerosis: A cellular action and mechanism-based perspective;Frontiers in Immunology;2022-12-21

3. Role of Statin in Reducing Cardiovascular Diseases in Human Immunodeficiency Virus (HIV) Patients: A Systematic Review;Cureus;2022-10-21

4. Probiotics Bring New Hope for Atherosclerosis Prevention and Treatment;Oxidative Medicine and Cellular Longevity;2022-09-24

5. A review on therapeutical potential of paeonol in atherosclerosis;Frontiers in Pharmacology;2022-08-04